To evaluate the Safety and efficacy of Unani formulation Majoon Supari paak in SayalÄ?n al-Rahim (Leucorrhoea)

Clinical Validation of Unani Pharmacopoeial formulation Majoon Supari paak in SayalÄ?n al-Rahim (Leucorrhoea)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/10/006290

Enrollment

300

Registered

2015-10-21

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N898- Other specified noninflammatory disorders of vagina

Interventions

Intervention1: Majoon Supari paak: 7gms twice Daily orally after meals with water for aduration of 4 weeks Control Intervention1: nil: nil

Eligibility

Inclusion criteria

Inclusion criteria: • Female patients in the age group of 13-45 years. • Patients having excessive white discharge with or without any of the following associated symptoms • Wajaâ?? al-Zahr (Backache) • Naqahat (General Weakness) • Faqr al-Dam (Anaemia) (8-10 mg % in females)

Exclusion criteria

Exclusion criteria: • Patients having acute/ acute on chronic/Chronic PIDs (as per the CDC Diagnostic Criteria attached as an annexure-IV) • Patients on long-term medications. • Patients on Oral Contraceptives/IUDs. • Patients taking hormonal therapy. • Any abnormal condition on p/s Examination. • Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
improvement in the sign and symptoms of SayalÄ?n al-Rahim (Leucorrhoea)Timepoint: 4 weeks	—

Secondary

Measure	Time frame
Hematological and biochemical assessments for safetyTimepoint: 4 weeks	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum57@gmail.com9810161758

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026